NAT COMMUN: Old medicines are used to inhibit tumor mitochondrial and angiogenesis.

To date, cancer remains an important health problem worldwide.
Although standard protocols and treatments for colon and breast cancer already exist, treatment needs are not met and new treatments are a priority, which can minimize the social and economic burden of cancer.
enhanced aerobic glycoenzyme is one of the hallmarks of cancer, and glycoenzyme itself has been presented as a potential chemotherapy target to treat cancer.
mitochondrial metabolism is a promising target for tumor growth mechanisms.
here, the researchers screened FDA-approved libraries to identify drugs that inhibit mitochondrial breathing.
beta1 blocker nebivolol specifically blocks oxidation phosphorylation of cancer cells by collaborating to inhibit the activity of mitochondrial respiratory chain Complex I and ATP synthase.
mechanism studies have shown that drug inhibition of Complex I is mediated by interfering with the phosphorylation of NDUFS7, and that inhibition of ATP synthase is performed through excessive expression of ATP enzyme inhibitor 1 (IF1) and binding to that enzyme.
it's worth noting that nebivolol can also inhibit tumor angiogenesis by inhibiting the proliferation of endothelial cells.
overall, the study proves that targeting mitochondria and angiogenesis can trigger metabolic and oxidative stress crises and limit the growth of colon and breast cancers.
Nebivolol has great prospects in the treatment of cancer patients, and it is worth further studying the new value of its old drugs.
.